This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Catalyst (CPRX) Down on TEVA's FDA Filing for Firdapse Generic
by Zacks Equity Research
Catalyst Pharmaceuticals (CPRX) receives a notice letter stating that Teva Pharmaceuticals has filed an application to the FDA seeking approval for a generic version of Firdapse.
UTHR or ESALY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
UTHR vs. ESALY: Which Stock Is the Better Value Option?
UTHR vs. ESALY: Which Stock Is the Better Value Option?
by Zacks Equity Research
UTHR vs. ESALY: Which Stock Is the Better Value Option?
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
by Andrew Rocco
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
UTHR vs. ESALY: Which Stock Is the Better Value Option?
by Zacks Equity Research
UTHR vs. ESALY: Which Stock Is the Better Value Option?
New Strong Sell Stocks for September 30th
by Zacks Equity Research
CGC, ESALY and META have been added to the Zacks Rank #5 (Strong Sell) List on September 30, 2022.
New Strong Sell Stocks for June 8th
by Zacks Equity Research
APAM, CNVY, and ESALY have been added to the Zacks Rank #5 (Strong Sell) List on June 8, 2022.
Best Income Stocks to Buy for March 1st
by Zacks Equity Research
GOGL, ESALY, and ADM made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 1, 2022
Citius (CTXR) Acquires Dr. Reddy's License for NHL Therapy
by Zacks Equity Research
Citius Pharmaceuticals (CTXR) acquires Dr. Reddy's exclusive license rights for E7777 to treat a rare form of NHL and other cancer indications.
Merck's (MRK) Keytruda Combo Meets Goal in Kidney Cancer Study
by Zacks Equity Research
Merck (MRK) and partner Eisai report positive top-line data from the phase III study evaluating Keytruda plus the latter's Lenvima for first-line treatment of patients with kidney cancer.
Avenue Therapeutics (ATXI) Misses Earnings Estimates in Q2
by Zacks Equity Research
Avenue Therapeutics (ATXI) reports a wider-than-expected loss in the second quarter of 2021.
New Strong Sell Stocks for July 6th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Xencor (XNCR) Jumps: Stock Rises 7.4%
by Zacks Equity Research
Xencor (XNCR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: Eisai, Martin Marietta and Columbia Sportswear
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eisai, Martin Marietta and Columbia Sportswear
The G20 Meeting Cometh: Global Week Ahead
by John Blank
The weekend's G20 meeting in Osaka, Japan -- starting on Friday and running into Saturday -- should be the week's main event. But it is a closer.
Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza
by Zacks Equity Research
Ocular (OCUL) clinches the FDA approval for the label expansion of Dextenza to treat ocular inflammation following ophthalmic surgery.
Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint
by Zacks Equity Research
Ocular's (OCUL) phase III study on OTX-TP for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma fails to achieve primary endpoint.
Catalent Acquires Gene Therapy Leader Paragon Bioservices
by Zacks Equity Research
Catalent (CTLT) acquires gene therapy leader Paragon Bioservices for $1.2 billion.
CannTrust Holdings (CTST) in Focus: Stock Moves 6.1% Higher
by Zacks Equity Research
CannTrust Holdings (CTST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off to a Good Start
by Zacks Equity Research
Catalyst (CPRX) posts narrower-than-expected loss and beats on revenues in the first quarter of 2019.
Zoetis (ZTS) Earnings Beat Estimates in Q1, Revenues Miss
by Zacks Equity Research
Zoetis???s (ZTS) earnings beat estimates but sales miss the same in the first quarter of 2019.
Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65%
by Zacks Equity Research
Achaogen (AKAO) files for bankruptcy in a district court. Shares slump 65% on the announcement.
Zogenix Gets Refusal to File Letter From FDA for Seizure Drug
by Zacks Equity Research
Zogenix (ZGNX) receives a Refusal to File letter from the FDA regarding its NDA for Fintepla for the treatment of seizures associated with Dravet syndrome.
United Therapeutics Discontinues PAH Drug After Study Fails
by Zacks Equity Research
United Therapeutics (UTHR) discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.
Why Eisai (ESALY) Could Be an Impressive Growth Stock
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Eisai (ESALY).